Throat swab DNA Extraction Kit |
EP036 |
ELK Biotech |
50T |
EUR 151 |
Human IgG antibody Laboratories manufactures the is ihe swab in the throat called sars test reagents distributed by Genprice. The Is Ihe Swab In The Throat Called Sars Test reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Test. Other Is products are available in stock. Specificity: Is Category: Ihe Group: Swab In
Fetal Throat Lysate |
ProSci |
0.1 mg |
EUR 500.1 |
Description: Fetal human throat tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The fetal human throat tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the throat tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The throat tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot. |
SD Dengue Duo NS1 Ag and IgG/IgM test |
Abbott |
10 tests/kit |
EUR 147.4 |
SD Dengue Duo NS1 Ag and IgG/IgM test |
Abbott |
25 tests/kit |
EUR 308 |
Swab In information
SARS-CoV-2 Rapid Antigen Test Nasal |
9901-NCOV-03G |
Roche Diagnostics |
25 Tests/Kit |
EUR 112.8 |
|
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke |
Recombinant human Protein disulfide-isomerase-like protein of the testis |
P2148 |
FN Test |
100ug |
Ask for price |
|
Description: Recombinant protein for human Protein disulfide-isomerase-like protein of the testis |
Paraffin Tissue Section - Human Throat Tumor: Squamous Cell Carcinoma of Pharynx |
T2235263-2 |
Biochain |
5 slides |
EUR 238 |
SARS-CoV-2 Purified Viral Lysate |
NAT41605-100 |
The Native Antigen Company |
0.1 |
EUR 454.17 |
Description: This virus was isolated from a patient with a respiratory illness who had returned from travel to the affected region of China and developed COVID-19 in January 2020 in Washington, USA. Sequence Strain: SARS-Related Coronavirus 2 (SARS-CoV-2, Isolate: USAWA1/2020) |
SARS-CoV-2 Purified Viral Lysate |
NAT41605-500 |
The Native Antigen Company |
0.5 |
EUR 2181.53 |
Description: This virus was isolated from a patient with a respiratory illness who had returned from travel to the affected region of China and developed COVID-19 in January 2020 in Washington, USA. Sequence Strain: SARS-Related Coronavirus 2 (SARS-CoV-2, Isolate: USAWA1/2020) |
Accu-Tell COVID-19 IgG/IgM Rapid Test |
GEN-B352-20tests |
Accu test |
20 tests |
EUR 283.2 |
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus. |
Accu-Tell COVID-19 IgG/IgM Rapid Test |
GEN-B352-40tests |
Accu test |
40 tests |
EUR 385.2 |
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus. |
SARS Coronavirus Envelope Protein (E. coli) |
REC31839-100 |
The Native Antigen Company |
0.1 |
EUR 412.07 |
Description: Recombinant protein manufactured in E. coli. Contains the N-terminus Envelope protein, 1-76 amino acids immunodominant regions. Immunoreactive with sera from SARS-infected individuals. |
SARS Coronavirus Envelope Protein (E. coli) |
REC31839-500 |
The Native Antigen Company |
0.5 |
EUR 1546.21 |
Description: Recombinant protein manufactured in E. coli. Contains the N-terminus Envelope protein, 1-76 amino acids immunodominant regions. Immunoreactive with sera from SARS-infected individuals. |
SARS-CoV-2 NSP14 Methyltransferase, Active |
REC31937-10 |
The Native Antigen Company |
0.01 |
EUR 392.93 |
Description: Recombinant SARS-CoV-2 non-structural protein 14 (NSP14) was expressed in E. coli using a C-terminal His tag. |
SARS-CoV-2 NSP14 Methyltransferase, Active |
REC31937-20 |
The Native Antigen Company |
0.02 |
EUR 540.92 |
Description: Recombinant SARS-CoV-2 non-structural protein 14 (NSP14) was expressed in E. coli using a C-terminal His tag. |
SARS-CoV-2 NSP14 Methyltransferase, Active |
REC31937-50 |
The Native Antigen Company |
0.05 |
EUR 768 |
Description: Recombinant SARS-CoV-2 non-structural protein 14 (NSP14) was expressed in E. coli using a C-terminal His tag. |
SARS Coronavirus Nucleoprotein (N-Term) (E. coli) |
REC31836-100 |
The Native Antigen Company |
0.1 |
EUR 412.07 |
Description: SARS Coronavirus Nucleoprotein (N-Term), also known as the nucleocapsid core antigen, is a recombinant protein manufactured in E. coli, comprising immunodominant region aa 1-49. Immunoreactive with sera from SARS-infected individuals. |
SARS Coronavirus Nucleoprotein (N-Term) (E. coli) |
REC31836-500 |
The Native Antigen Company |
0.5 |
EUR 1546.21 |
Description: SARS Coronavirus Nucleoprotein (N-Term), also known as the nucleocapsid core antigen, is a recombinant protein manufactured in E. coli, comprising immunodominant region aa 1-49. Immunoreactive with sera from SARS-infected individuals. |
SARS Coronavirus Nucleoprotein (C-Term) (E. coli) |
REC31837-100 |
The Native Antigen Company |
0.1 |
EUR 412.07 |
Description: SARS associated coronavirus nucleocapsid recombinant antigen immunodominant region (aa 340-390). Immunoreactive with sera from SARS-infected individuals with minimum specificity problems. |
SARS Coronavirus Nucleoprotein (C-Term) (E. coli) |
REC31837-500 |
The Native Antigen Company |
0.5 |
EUR 1546.21 |
Description: SARS associated coronavirus nucleocapsid recombinant antigen immunodominant region (aa 340-390). Immunoreactive with sera from SARS-infected individuals with minimum specificity problems. |
SARS Coronavirus Membrane Protein (Matrix) (E. coli) |
REC31838-100 |
The Native Antigen Company |
0.1 |
EUR 412.07 |
Description: Recombinant protein manufactured in E. coli. Contains duplicate Membrane (also known as Matrix) immunodominant region sequences fused with a proprietary linker and His-tag. Immunoreactive with sera from SARS-infected individuals. |